Drug Profile
Research programme: heat shock protein cancer vaccine - GlaxoSmithKline
Alternative Names: heat shock protein cancer vaccine research programme - GlaxoSmithKline; hsp110-gp100 vaccineLatest Information Update: 23 Jan 2008
Price :
$50
*
At a glance
- Originator GlaxoSmithKline
- Class Cancer vaccines
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- Discontinued Malignant melanoma
Most Recent Events
- 23 Jan 2008 Discontinued - Preclinical for Malignant melanoma in USA (unspecified route)
- 24 Jul 2003 Preclinical trials in Malignant melanoma in USA (unspecified route)